Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million

▤ Summary

Curasight completed a directed share issue that raised about DKK 20 million from Nordic, international, institutional, and professional investors. The company plans to use the capital to strengthen working capital and fund clinical development of uTRACE and uTREAT through H1 2027. It also intends to finalize the next-generation peptide for uTREAT, submit an FDA IND for brain cancer, and prepare next-stage clinical studies. In parallel, Curasight renegotiated its Fenja Capital loan and extended the maturity date to 30 June 2027.

$ Funding

▦ Linked Companies